# Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

> **NCT06601127** · PHASE2 · RECRUITING · sponsor: **Tianjin Institute of Pharmaceutical Research Co., Ltd** · enrollment: 600 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** Tiprogrel
- **DRUG:** Tiprogrel
- **DRUG:** Clopidogrel

## Key facts

- **NCT ID:** NCT06601127
- **Lead sponsor:** Tianjin Institute of Pharmaceutical Research Co., Ltd
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-21
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06601127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06601127, "Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06601127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*